Call for Proposals

SPARK NS supports translational research projects at any stage of development between target identification and entry into clinical trials. Our inaugural 2024 program, which is underway, and our latest 2025 program focus on Parkinson’s disease.

Learn more about our programs

Selected projects receive up to $2,000,000 in milestone-based funding over the duration of a SPARK NS two-year program, including discretionary funding for PIs of $50,000 per year. Remaining funds are dispersed based on development plans jointly created for each selected project by the project PI and SPARK NS. Not all funds awarded necessarily go to a PI’s laboratory. For example, funds for work done by vetted contracted research organizations or academic research facilities are paid by SPARK NS directly to these organizations.

Learn more about how our programs work in the Program Description and Application Guidelines PDF.

SPARK NS programs provide PIs with funding, education, mentorship, and networking opportunities over the course of a two-year immersive program. The programs use a proven model for translational research developed and refined at Stanford University School of Medicine since 2006. The model has an exceptional 50%³ success rate at advancing promising academic discoveries through the translational research phase as measured by three criteria: advancing projects to clinical trials; licensing to an existing company; licensing to a startup.

Learn more about how SPARK NS programs are different

SPARK NS accepts applications from biomedical researchers at academic or nonprofit research institutions. We value diversity and are committed to creating a collaborative and inclusive research environment. Applicants from all backgrounds and experiences are encouraged to apply. For our latest program, the 2025 Parkinson’s Disease Translational Research Program, we are accepting applications from PIs in the United States, Canada, United Kingdom, and Europe.

Each application for a SPARK NS program must be completed by a single PI who holds a laboratory head position at a nonprofit academic or research institution. The PI is the responsible person for all program activities and requirements. The PI may name up to three co-investigators from their own or collaborating institutions. The PI may also list on the application an unlimited number of researchers as project team members, including post-doctoral fellows, senior scientists, and students.

The selection committee includes scientists who are generally familiar with relevant experimental methods and the subject matter, industry leaders with expertise in the various stages of the development and commercialization of therapeutics, and SPARK NS staff. Applicants for a SPARK NS program initially submit a written proposal describing their proposed product, which is reviewed by a selection committee. The selection committee choses finalists from the pool of applicants. SPARK NS makes the final decisions about which projects to admit to the program.

SPARK NS has 50+ industry expert advisors with extensive experience and domain knowledge in every aspect of therapeutic discovery and development, from the lab to the clinic. Their areas of expertise include diagnostics and biomarkers, medicinal chemistry, antibody engineering, formulation, clinical trial designs, clinical operations, medical affairs, regulatory, pharmacology, legal and licensing, intellectual property, pharma business development, entrepreneurship, venture capital, and more.

Applications are evaluated on the following criteria:

Clinical need. Projects must clearly define an unmet clinical need in the Parkinson’s disease space.

Underlying biology/technology. Projects must have a robust and novel approach that will lead to a first-in-class therapeutic.

Feasibility of translational objectives. Projects must have translational objectives with a high probability of being accomplished during the two-year program.

Potential applicants are encouraged, but not required, to participate in an Optional Pre-Submission Review by submitting a non-confidential topline description (short project summary not to exceed 250 words) and/or graphical abstract for review by June 28, 2024. Within two weeks of submission, applicants will receive feedback on whether their proposal is within the scope of the 2025 SPARK NS Translational Research Program. The pre-submission review is optional and does not impact the overall outcome of the application.

Submit Optional Pre-Submission Review

The dates for finalist presentations associated with a specific SPARK NS program are published early in the application process and well in advance of the dates. PIs who are not available to present on the required dates should not apply to the program.

Learn more about participant expectations in the Program Description and Application Guidelines PDF.

Given the importance of collaboration with peers and industry expert advisors to the success of translational research, PIs who cannot attend scheduled education and training courses or virtual/in-person project updates and progress meetings should not apply to the program.

Learn more about participant expectations in the Program Description and Application Guidelines PDF.

Applicants should not submit a project development plan or budget as part of the initial application or finalist presentation. Once projects are selected for a SPARK NS program, a project manager is assigned to each project. SPARK NS and the project PI subsequently work together on a development plan that includes a budget.

Learn more about our application process and timeline in the Call for Proposals PDF.